HC Wainwright Reaffirms “Buy” Rating for Chimerix (NASDAQ:CMRX)

HC Wainwright restated their buy rating on shares of Chimerix (NASDAQ:CMRX) in a research note released on Wednesday,Benzinga reports. They currently have a $11.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Chimerix’s Q4 2024 earnings at ($0.24) EPS, Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.26) EPS and FY2026 earnings at ($0.99) EPS.

A number of other analysts also recently issued reports on the company. Wedbush reaffirmed an “outperform” rating and set a $6.00 price target on shares of Chimerix in a report on Tuesday. StockNews.com upgraded shares of Chimerix from a “sell” rating to a “hold” rating in a research report on Wednesday, August 21st.

Chimerix Trading Up 0.3 %

Chimerix stock opened at $2.95 on Wednesday. The stock has a market cap of $265.32 million, a P/E ratio of -3.14 and a beta of 1.02. The company has a fifty day simple moving average of $1.07 and a 200-day simple moving average of $0.96. Chimerix has a 12-month low of $0.75 and a 12-month high of $3.39.

Institutional Trading of Chimerix

Several institutional investors and hedge funds have recently made changes to their positions in the company. Valeo Financial Advisors LLC lifted its holdings in shares of Chimerix by 566.9% in the 3rd quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 69,505 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Chimerix by 66.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock worth $321,000 after acquiring an additional 138,098 shares during the last quarter. Finally, Marshall Wace LLP acquired a new position in shares of Chimerix in the 2nd quarter valued at $137,000. 45.42% of the stock is owned by hedge funds and other institutional investors.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.